Cryptococcal therapies and drug targets: the old, the new and the promising.
about
High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.Antifungal adjuvants: Preserving and extending the antifungal arsenalCalcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach.Repression of Proteases and Hsp90 Chaperone Expression Induced by an Antiretroviral in Virulent Environmental Strains of Cryptococcus neoformans.Linear Epitopes of Paracoccidioides brasiliensis and Other Fungal Agents of Human Systemic Mycoses As Vaccine CandidatesThe antifungal pipeline: a reality check.The lysine biosynthetic enzyme Lys4 influences iron metabolism, mitochondrial function and virulence in Cryptococcus neoformans.Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience.Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.Dissecting the Roles of the Calcineurin Pathway in Unisexual Reproduction, Stress Responses, and Virulence in Cryptococcus deneoformans.Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay.Mechanisms of Pulmonary Escape and Dissemination by Cryptococcus neoformans.Synthesis, stability and mechanistic studies of potent anticryptococcal hexapeptides.Synthesis and Antifungal Screening of 2-{[1-(5-Alkyl/arylalkylpyrazin-2-yl)ethylidene]hydrazono}-1,3-thiazolidin-4-ones.Control of Cryptococcus Gattii Biofilms by an Ethanolic Extract of Cochlospermum Regium (Schrank) Pilger Leaves.
P2860
Q33875911-92FA2AF9-0BF4-433C-A52C-1C72CE7C4E8FQ37705308-A3D1282F-CDEE-4C86-9DF9-A463BF6E9904Q38871364-171A3674-6710-465F-883E-49BB1B44C946Q39137674-07BCE7BA-94AA-4A08-A196-5ABDAB84579EQ39201536-A821630B-9654-4BFC-9C84-55C1C0407DABQ39299949-0AA944FF-FDA6-4985-8D81-3D1C9BD6388EQ39826377-A4E627A6-2A36-4980-9E8E-9E69F247D725Q40090559-21BF3356-99AB-4068-B35F-9D8BED3F9AA9Q40202904-B18EC4CF-8414-4DF5-B691-5022AE9D7044Q47301330-86475EAE-E6C9-4306-9599-DCBCB6C14034Q48112438-1FDB4EC7-C217-4019-9C93-532794013922Q49804343-A684B374-74B3-4AED-AEE3-360BBB866C5BQ50937911-74C75145-1F16-4F04-BDC7-BE63FB909962Q53663010-3EFB2C02-3D7D-49FE-82F0-05DE3DC6E247Q55492466-9EA61BE7-8014-4A10-AF07-9B6F2C6A4448
P2860
Cryptococcal therapies and drug targets: the old, the new and the promising.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cryptococcal therapies and drug targets: the old, the new and the promising.
@en
type
label
Cryptococcal therapies and drug targets: the old, the new and the promising.
@en
prefLabel
Cryptococcal therapies and drug targets: the old, the new and the promising.
@en
P2860
P356
P1476
Cryptococcal therapies and drug targets: the old, the new and the promising.
@en
P2093
Carolina Coelho
P2860
P304
P356
10.1111/CMI.12590
P577
2016-03-15T00:00:00Z